Fed Circuit revives bid to invalidate robotic surgery patent
The US Court of Appeals for the Federal Circuit has renewed Auris Health’s attempt to invalidate Intuitive Surgical’s patent covering a robotic surgical tool.
Texas jury says 3Shape must pay $12m over dental scanner
A Texas jury has handed a $12 million victory to an Israeli company after finding that Danish company 3Shape’s dental scanner infringed one of its patents.
Fed Circ revives claims in St Jude’s catheter patent suit
Abbot-owned St Jude Medical will have to defend claims that its catheters infringe a company’s revived patent.
Medtech groups say ‘unlawful’ DMCA exemption should be waived
Medical device companies have asked a US federal judge to eliminate an exemption that allows the bypassing of technological protections for copyrighted software if it is in service of using or repairing medical devices.
Illumina gets $8m plus injunction from DNA sequencing suit
DNA-sequencing company Illumina has convinced a California court to bar Chinese pharma firm BGI Genomics from selling technology that infringes its genome-sequencing patents.
Therabody launches infringement charge against TJ Maxx, others
Therabody has sued TJ Maxx’s parent company, alongside five “unauthorised” Amazon resellers for patent and trademark infringement, claiming they sell “knockoff” massage gun products.
FujiFilm sues Butterfly Network over ultrasound patents
A subsidiary of Tokyo-based FujiFilm has announced that it has filed a patent infringement lawsuit against ultrasound machine maker Butterfly Network.
Fed Circ denies bid to reverse favourable J&J ruling
The US Court of Appeals for the Federal Circuit has affirmed two Patent Trial and Appeal Board rulings that a Johnson & Johnson subsidiary’s patent is valid and infringed.
Arthrex petitions Fed Circ again over ‘inferior officers’
Arthrex says that it did not get the “remedy” ordered by the US Supreme Court in its landmark case against Smith & Nephew.
Fed Circ rejects Sanofi’s bid to resurrect Lantus patents
The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.